Cellular Dynamics is the world’s largest producer of fully functional human cells derived from induced pluripotent stem (iPS) cells. We have multiple cell types in development and welcome inquiries about in vitro assay applications and collaborative opportunities with the following cell types:
Cellular Dynamics International (CDI) is developing iCell® Hepatocytes, human hepatocytes derived from iPS cells. These products will provide, for the first time, access to commercial quantities of high quality, high purity human liver cells for preclinical drug discovery, hepatotoxicity testing, and disease research.
Liver toxicity and alterations of hepatic physiology are frequently occurring reasons for preclinical failure during drug development. In addition, drug-induced liver injury is the most common reason for market withdrawal of approved drugs due to safety concerns. Liver diseases associated with drug toxicity can be attributed, in large part, to the lack of biologically relevant and predictive model systems. Current hepatocyte model systems include primary human hepatocytes harvested from cadavers, immortalized cell lines, and animal models. Each of these presents limitations in functionality, reproducibility, and/or availability. iCell Hepatocytes will overcome these limitations and provide a reliable source of well-characterized, highly reproducible, and readily available human hepatocytes for preclinical drug development and safety testing.
Currently in development, iCell Hepatocytes will be highly purified, terminally differentiated human hepatocytes derived from iPS cells using CDI’s proprietary differentiation and purification protocols. The cells will exhibit characteristic mature hepatocyte morphology, gene and protein expression (e.g. albumin, alpha-1-antitrypsin, ASGR1, P450 enzymes, transporters) and intrinsic metabolism functions (e.g. glycogen and lipid storage). iCell Hepatocytes will be well-characterized for Phase I and II metabolism, including P450, UDP glucuronosyltransferase (UGT), sulfotransferase (ST) and glutathione-S-transferase (GST) activity, as well as drug transport function.
Cellular Dynamics International (CDI) is actively engaged in developing multipotent hematopoietic progenitor cells. The capacity to generate and expand highly purified human hematopoietic progenitor cells benefits multiple areas of cellular therapy, including cancer immunotherapy, induced transplant tolerance, and treatment for autoimmune diseases.
CDI’s research, including the development of a defined, stroma-free, serum-free, automatable process for reproducible production of hematopoietic cells from iPSCs, was supported by SBIR grants awarded by the National Science Foundation:
Phase I: SBIR #0712181, $150,000
Phase II: SBIR #0823027, $616,000
Thus far CDI has generated hematopoietic progenitor cells derived from iPSCs into diverse mature blood cell types:
We are actively seeking collaborative partnerships to develop this cell type and assays, and we welcome inquiries.Email us or contact Cellular Dynamics: